Clinical trial

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

NCT00242567

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-12-01

PhasePHASE3

Study timeline

Study start (unknown)2005-12-01Date precision: month

Registry last updated2014-05-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Zoledronic AcidDRUG · verified · RxNorm: zoledronic acid

Androgen Deprivation Therapy (ADT)DRUG

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

SeoulSouth Korea1 TaipeiTaiwan1 BeijingChina1 ShanghaiChina1 São PauloBrazil1 TaichungTaiwan1 BangkokThailand1 TaoyuanTaiwan1 Porto AlegreBrazil1 BusanSouth Korea1 ChongqingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00242567 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.